About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Mab Thera to Be Made Available by for Rheumatoid Arthritis Patients in UK by NHS

by Medindia Content Team on August 23, 2007 at 12:26 PM
Font : A-A+

Mab Thera to Be Made Available by for Rheumatoid Arthritis Patients in UK by NHS

UK's National Health Services has decided to make available Mab Thera for rheumatoid arthritis patients nationwide.

The decision follows a recommendation by NHS watchdog the National Institute for Health and Clinical Excellence (Nice).

Advertisement

Thousands of rheumatoid arthritis patients will stand to benefit and arthritis charities have hailed the decision.

Rheumatoid arthritis is a painful and sometimes crippling autoimmune disease that affects an estimated 400,000 people in the UK. It occurs when the immune system attacks the joints, causing swelling and damaging cartilage and bone.
Advertisement

MabThera, the Roche brand name of the drug rituximab, is a synthetic antibody that targets one of the key immune system cells involved in rheumatoid arthritis.

Antibodies are molecules in the blood or secretory fluids that tag, destroy, or neutralize bacteria, viruses, or other harmful toxins.

The drug is already freely available to patients in Scotland after a similar decision by Nice's counterpart, the Scottish Medicines Consortium.

MabThera's relatively low cost is part of the reason for its approval by Nice. At £4,657 to treat one patient for a year the drug is almost half the price of other therapies.

The total cost of the disease in England alone, including health care and indirect costs such as lost working days, has been estimated at up to £1.2bn a year. Anti-TNF (tumour necrosis factor) drugs, the most advanced current treatment for severe rheumatoid arthritis, cost around £9,000 a year.

These drugs work by switching off tumour necrosis factor (TNF), which stimulates cells to produce the inflammation response that leads to pain and swelling of the joints.

MabThera will be available to NHS patients who fail to improve after first being given an anti-TNF drug.

A spokeswoman for the Arthritis Research Campaign, which sponsors research into the disease, said Nice's decision gave patients who failed to respond to anti-TNF therapy "a lifeline".

An article in the June edition of medical journal The Lancet highlighted the success of MabThera in slowing the progression of rheumatoid arthritis. The study found it reduced symptoms by more than 50% for more than a third of patients.

MabThera is claimed as the first and only selective B cell therapy for rheumatoid arthritis offering a fundamentally different treatment approach.

B cells play a key role in driving the disease process and MabThera is thought to break this process.

Both the European Union and the US Food and Drug Administration approved the drug last year.

Rheumatoid Arthritis is one of the most common forms of autoimmune disease which affects more than 21 million people worldwide, with as many as 3 million sufferers in Europe alone.

The term "autoimmune disease" refers to a varied group of more than 80 serious, chronic illnesses that involve almost every human organ system. It includes diseases of the nervous, gastrointestinal, and endocrine systems as well as skin and other connective tissues, eyes blood, and blood vessel. In all of these diseases, the underlying problem is similar--the body's immune system becomes misdirected, attacking the very organs it was designed to protect. For reasons we do not understand, about 75 percent of autoimmune diseases occur in women, most frequently during the childbearing years.



Source: Medindia
GPL/J
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Top 7 Benefits of Good Oral Hygiene
Healthy and Safer Thanksgiving 2021
Long-Term Glycemic Control - A Better Measure of COVID-19 Severity
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Osteoarthritis Rheumatoid Arthritis Oligoarthritis Spondylolisthesis Chemotherapy Chemotherapy Drugs Knee Replacement Reactive Arthritis Hypermobility Syndrome Autoimmune Disorders 

Recommended Reading
New Drug for Rheumatoid Arthritis Looks Promising.
Patients with rheumatoid arthritis hopes have been raised with Roche announcing that its new drug .....
Obesity Worsens Life Quality of Rheumatoid Arthritis Patients
Researchers have found that obesity worsens the quality of life of patients with rheumatoid ......
Autoimmune Disorders
Autoimmune disorders occur when the immune system fails to recognize the body as ‘self’ and attacks ...
Chemotherapy
‘Chemo’ means medicine or ‘drug’; ‘therapy’ means ‘treatment’. Chemotherapy refers to the use of cy...
Chemotherapy Drugs
Chemotherapy drugs perform like ‘magic bullets’ to destroy cancer cells in the body....
Hypermobility Syndrome
Hypermobility Syndrome is a condition in which a person can move his joints far beyond the normal .....
Knee Replacement
Make sprinting a possibility! Relieve chronic arthritic pain by having a knee replacement done at ...
Oligoarthritis
Most parents when told that their child has arthritis find it hard to believe it, as arthritis is re...
Osteoarthritis
Osteoarthritis is one of the commonest joint disorder and occurs as we age due to wear and tear of a...
Reactive Arthritis
Reactive arthritis is an autoimmune condition. Ankylosing spondylitis, psoriatic arthritis are disor...
Rheumatoid Arthritis
Rheumatoid arthritis is a chronic inflammatory disease that causes pain, swelling, stiffness and los...
Spondylolisthesis
Spondylolisthesis is a condition of the lower spine in which one of the bones of the vertebral colum...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use